Skip to main content
SpringerLink
Log in

The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing–remitting multiple sclerosis patients

Twenty–four months follow–up

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

The aim of the present study was to evaluate the efficacy of the combination of cyclophosphamide (CTX) and interferon beta (IFN β) in a group of relapsing remitting (RR) multiple sclerosis (MS) patients who experienced treatment failure during IFN β therapy. It is the general experience that immunomodulatory agents (IMA) are only partially effective in RR patients. Recent data on the efficacy of immunosuppressive therapies for these patients are encouraging. The anti–inflammatory and immunosuppressive effects of CTX have been utilized to treat selected cases of multiple sclerosis with a progressive and worsening course as rescue therapy. Thirty RR MS patients with clinically defined MS who experienced treatment failure during IFN β therapy (2 or more relapses per year or 1.5 EDSS point worsening in one year) were enrolled in the study and treated with CTX iv pulse therapy added to IFN β and followed up for 24 months. As primary endpoints we evaluated the yearly relapse rate. We also evaluated the percentage of patients free of relapses and of EDSS variations. We analysed the results at one year before entry (T0: IFN β alone), 12 (T1) and 24 (T2) months after entry. Brain MRI was performed at T0, at T1 and T2. The 30 RR patients who had experienced a high number of relapses (r r =1.4) at T0 showed a significant improvement in yearly relapse rate (rr = 0.4) at T1 and a further improvement (rr = 0.17) at T2 (p < 0.001). The percentage of patients free of relapse was 70% at T2 (p < 0.0001). EDSS score changed from 2.6±1.23 at T0 to 2.2 ± 1.5 at T2, showing only a trend of improvement.No significant variation of MRI lesion load and no severe adverse events were recorded during the study. These data showed that the combination of CTX plus IFN β halted the progression of disease in active and deteriorating MS patients suggesting the necessity of RCTs to test the efficacy of this combination therapy in active RRMS patients or in patients who experienced treatment failure in response to disease modifying drugs (DMDs).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL (1988) Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-years experience in 164 patients. Neurology 38:9–14

    Google Scholar 

  2. Edan G, Miller D, Clanet C, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Dousset V, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraund O (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118

    PubMed  Google Scholar 

  3. Elison GW, Myers LW (1978) A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis. Neurology 28:132

    PubMed  Google Scholar 

  4. Gobbini MI, Smith ME, Richert ND, Frank JA, Mc Fahrland HF (1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99:142–149

    Article  PubMed  Google Scholar 

  5. Gonsette R, Demonty L, Delmonte P (1977) Intensive immunosuppression with cyclophosphamide in multiple sclerosis: follow-up of 110 patients for 2–6 years. J Neuroimunol 214:173–181

    Google Scholar 

  6. Goodkin DE, Plencer S, Palmer SJ, Teetzen M, Hartsgaard D (1987) Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs nonmaintenance therapy. Arch Neurol 44:823–827

    PubMed  Google Scholar 

  7. Hafler DA, Weiner HL (1995) Immunological mechanisms and therapy in multiple sclerosis. Immunol Rev 144:75–107

    PubMed  Google Scholar 

  8. Hauser S, Dawson DM, Lehrich JR, Beal Mf, Kevy SV, Propper RD, Mills JA, Weiner HL (1983) Intensive immunosuppression in progressive multiple sclerosis: A randomised, three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl Med 1983:173–180

    Google Scholar 

  9. Hommes OR, Lamers KJB, Reekers P (1980) Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 223:177–190

    Article  PubMed  Google Scholar 

  10. IFNB MS Study Group (1993) Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial The IFNB Multiple Sclerosis Study Group. Neurology 43:655–661

    PubMed  Google Scholar 

  11. Interferon beta-1b and secondary progressive multiple sclerosis: licence and extension (2000) Useful, but further assessment required. Prescrire Int 9(48):110–111

    PubMed  Google Scholar 

  12. Jacobs LD, Cookfair DL, Rudick RA, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294

    Article  PubMed  Google Scholar 

  13. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group (1998/2001) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 57(12 Suppl 5):S46–S53

    Google Scholar 

  14. Kahn OA, Zvartau-Hind M, Caon C, Din MU, Cochran M, Lisak D, Tselis AC, Kamholz JA, Garben JV, Lisak RP (2001) Effects of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7:185–188

    PubMed  Google Scholar 

  15. Kallen B, Dohlsten M, Klementsson H (1986) Effect of cyclophosphamide pretreatment on autoimmune encephalomyelitis in rats. Acta Neurol Scand 73(4):338–344

    PubMed  Google Scholar 

  16. Kappos L, Heun R, Mertens HG (1990) A 10 years matched-pairs study comparing azathioprine and no immunosuppression in multiple sclerosis. Eur Arch Psychiatry Neurol Sci 240:34–38

    Google Scholar 

  17. Kappos L (1988) Clinical trials of immunosuppression and immunomodulation in multiple sclerosis. J Neuroimmunol 20:216–268

    Article  Google Scholar 

  18. Karussis DM, Slavin S, Ben-Nun A, Ovadia H, Vourka-Karussis U, Lehmann D, Mizrachi-Kol R, Abramsky O (1992) Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 39(3):201–210

    Article  PubMed  Google Scholar 

  19. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC (1998) Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: Rheumatologic and renal diseases. Ann Intern Med 128(12):1021–1028

    PubMed  Google Scholar 

  20. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC (1998) Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 129(1):49–58

    PubMed  Google Scholar 

  21. Likosky WH (1988) Experience with cyclophosphamide in multiple sclerosis: the cons. Neurology 38(Suppl. 7):14–18

    PubMed  Google Scholar 

  22. Lisak RP (1988) Overview of the rationale for immunomodulating therapies in multiple sclerosis. Neurology 38 (Suppl. 2):5–8

    Google Scholar 

  23. Mancardi GL, Saccardi R, Filippi M, et al. (2001) Autologus hemopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57:62–68

    PubMed  Google Scholar 

  24. Martin R, Mc Farland HF, Mc Farln DE (1992) Immunological aspects of demyelinating diseases. Ann Rev Immunol 10:153–187

    Google Scholar 

  25. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reigold SC, Sandberg-Wollheim M, Sibley W, Thompson A, Van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines for the international Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1): 121–127

    Article  PubMed  Google Scholar 

  26. Minagawa H, Takenaka A, Itoyama Y, Mori R (1987) Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide. J Neurol Sci 78(2):225–235

    Article  PubMed  Google Scholar 

  27. Ormerod IE, Miller DH, Mc Donald WI, et al. (1987) The role of MRI imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 110:1579–1616

    PubMed  Google Scholar 

  28. Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC (2004) A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci 223(1):69–71

    PubMed  Google Scholar 

  29. Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A (2001) Combination of cyclophosphamide and interferon β halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosur Psychiatry 71:404–407

    Article  Google Scholar 

  30. Patti F, Reggio E, Palermo F, Fiorilla T, Politi G, Nicoletti A, Reggio A (2004) Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 251(12):1502–1506

    Article  PubMed  Google Scholar 

  31. Perini P, Marangoni S, Tzinteva F, Ranzato F, Tavolato B, Gallo P (2001) Two years therapy of secondary progressive multiple sclerosis (SPMS) with pulse intravenous cyclophosphamide/ methylprednisolone. Clinical and MRI data. Mult Scler 7:S62

    Google Scholar 

  32. Poser CM, Paty DW, Scheinberg L, Mc- Donald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231

    PubMed  Google Scholar 

  33. PRISMS (Prevention of Relapses and Disability by interferon-beta 1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomized doubleblind, placebo-controlled study of interferon beta 1a in relapsing-remitting multiple sclerosis. Lancet 352: 1498–1504

    Article  PubMed  Google Scholar 

  34. Smith D (2004) Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J Neurol Sci 223(1):73–79

    PubMed  Google Scholar 

  35. The Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441–446

    PubMed  Google Scholar 

  36. Weiner HL, Cohen JA (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2:142–154 (Review)

    Google Scholar 

  37. Weiner HL, Hafler DA (1988) Immunotherapy of multiple sclerosis. Ann Neurol 23:211–222

    Article  PubMed  Google Scholar 

  38. Weiner HL, Mackin GA, Ovar EJ, et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43:910–918

    PubMed  Google Scholar 

  39. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. (1997) Treatment of “transitional MS”with cyclophosphamide and methyl-prednisolone (CTX-MP) followed by interferon β (abstract). Neurology 48(Suppl 2):A341

    Google Scholar 

  40. Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Senechal O, Vermersch P (2004) Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 218(1–2):73–77

    Article  PubMed  Google Scholar 

  41. Zephir H, De Seze J, Senechal O, Stojkovic T, Ferriby D, Deliss B, Dubus B, Verier A, Hautecoeur P, Vermersch P (2002) Traitement des formes progressives de sclerose en plaques par la cyclophosphamide. Rev Neurol (Paris) 158(1):65–69

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre of Multiple Sclerosis and Degenerative Disease of the Nervous System, University of Catania, Via Conti 6, 95125, Catania, Italy

    E. Reggio MD, A. Nicoletti, T. Fiorilla, A. Reggio & F. Patti

  2. Dept. of Radiology, University of Catania, Catania, Italy

    G. Politi

Authors
  1. E. Reggio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Nicoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Fiorilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Politi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Reggio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Patti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Reggio MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reggio, E., Nicoletti, A., Fiorilla, T. et al. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing–remitting multiple sclerosis patients. J Neurol 252, 1255–1261 (2005). https://doi.org/10.1007/s00415-005-0857-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-005-0857-1

Key words

Search

Navigation